Single-Agent Belantamab Mafodotin for Relapsed/Refractory Multiple Myeloma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Blood Cancer Journal
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Single-Agent Belantamab Mafodotin for Relapsed/Refractory Multiple Myeloma: Analysis of the Lyophilised Presentation Cohort From the Pivotal DREAMM-2 Study
Blood Cancer J 2020 Oct 23;[EPub Ahead of Print], PG Richardson, HC Lee, AO Abdallah, AD Cohen, P Kapoor, PM Voorhees, A Hoos, K Wang, J Baron, T Piontek, J Byrne, S Richmond, RC Jewell, J Opalinska, I Gupta, S LonialFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.